Coty (COTY) Q4 Earnings: Taking a Look at Key Metrics Versus Estimates

Coty (COTY) reported Q4 revenue of $1.25 billion for the period ended June 2025, an 8.1% year-over-year decline, yet it surpassed the Zacks Consensus Estimate by 4.07%. Conversely, the company posted an EPS of -$0.05, a significant miss against the $0.01 consensus estimate and worsening from -$0.03 a year ago. While Prestige segment revenue exceeded expectations, the Consumer Beauty segment's Adjusted Operating Income notably missed estimates, reporting a $-7 million loss against a $-1.36 million estimate. Coty shares have underperformed the broader market, declining 2.4% over the past month.

Analysis

Coty's Q4 results for the period ended June 2025 present a challenging operational picture, where a top-line beat masks significant underlying weakness. While revenue of $1.25 billion surpassed the Zacks Consensus Estimate by 4.07%, it simultaneously represents an 8.1% year-over-year decline. The bottom-line performance is more concerning, with an EPS of -$0.05 marking a substantial -600% negative surprise against the consensus estimate for a $0.01 profit and a deterioration from the -$0.03 EPS a year prior. A segmental breakdown reveals that while both Prestige and Consumer Beauty revenues exceeded analyst estimates, they still fell 5.3% and 12.3% year-over-year, respectively. Profitability is a key pressure point, as the Consumer Beauty segment's adjusted operating loss of $7 million was significantly wider than the $1.36 million loss analysts had projected. This weak fundamental performance is reflected in the stock's recent -2.4% return over the past month, underperforming the S&P 500 composite's +2% gain.

Key Decisions for Investors

• Investors should heavily discount the top-line revenue beat, as the severe -600% EPS miss and wider-than-expected operating loss in the Consumer Beauty segment indicate significant margin erosion and operational challenges.
• Given the year-over-year revenue declines across both Prestige (-5.3%) and Consumer Beauty (-12.3%) divisions, it is prudent to reassess the company's growth outlook and monitor for signs of market share loss or demand stabilization.
• The stock's recent underperformance relative to the broader market is justified by these results, and caution is warranted; consider holding off on new long positions until management provides a clear strategy to address the deteriorating profitability.